drugset / Trial / NCT01699464

A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months

NCT01699464

Phase 2 Completed 211 enrolled Aerie Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

A double-masked, parallel study of AR-12286 Ophthalmic Solution 0.5%, or 0.7% (q.d., PM) or timolol maleate Ophthalmic Solution, 0.5% (b.i.d.), O.U. for 3 months.

Timeline

Start
2012-10
Primary completion
2013-04
Completion
2013-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Timolol Other / unclassified 0.5 % Other
Subject VEROSUDIL Small molecule 0.5 % Other
Subject VEROSUDIL Small molecule 0.7 % Other